VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
|Videos|October 8, 2021
New Data Surrounding Pediatric Pneumococcal Disease Shows Promise
Musey discussed the highlights of the new data and how these 2 studies are different than previous studies in this topic area.
Advertisement
Pharmacy Times spoke with Luwy Musey, executive director in biologics and vaccines clinical research at Merck, about the results from two phase 3 pediatric studies surrounding pneumococcal disease that was presented at the IDWeek 2021 conference.
Musey discussed the highlights of the new data and how these 2 studies are different than previous studies in this topic area.
Advertisement
Related to this article
Convenience should not replace connection.
Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with the rare airway disease.
Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
2
FDA Grants Accelerated Approval to First Plasmid DNA-Based Immunotherapy for Recurrent Respiratory Papillomatosis
3
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
4
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
5